Turkish officials announced on Thursday that a vaccine from the Chinese company Synovac has an efficacy rate of 91.25 percent, but the discovery was based on preliminary results from a small clinical trial and no data were published in a journal Or was not posted online.
The announcement came a day after another ambiguous news conference, about Synovac’s vaccine in Brazil. Officials there were expected to provide detailed results from another test, but only reported that the vaccine’s efficacy rate was over 50 percent.
The Turkish trial involved a total of 7,371 volunteers, but the efficacy data presented by the infectious disease specialist, Health Anal, were based on only 1,322 participants, of whom 752 received an actual vaccine and 570 received a placebo.
Dr. Unal stated that 26 of the volunteers receiving placebo developed Kovid-19, while only three of the vaccinated volunteers fell ill. He and his colleagues did not share their data in writing.
Health Minister Fahretin Koka said, “Now we are sure that this vaccine is effective and safe on the Turkish people.”
Synovac did not issue a public statement about the trial, nor commented on the trial in Brazil.
The small number of volunteers on which Turkish researchers based their calculation of efficacy raised questions about the certainty of their findings. The more people participate in clinical vaccine testing, the greater its statistical power.
In contrast, Pfizer and BioNotech presented data to 36,523 people to show that the vaccine had an efficacy rate of 95 percent. For their vaccine, 162 people who developed placebo, Kovid, developed the vaccine, compared to eight in the group.
Turkey signed an agreement with Synovac for 50 million doses of the vaccine. Mr. Coca said that the first three million doses are scheduled to arrive in Turkey on Monday. Mr. Koka said that Turkey would also receive 4.5 million doses of the Pfizer-BioNotech vaccine by the end of March. He said about 1 million doses are expected to arrive in late January.
Coronavac, as Synovac calls its vaccine, is made from the slain coronavirus. The method for making the vaccine is one of the oldest, used by Jonas Salk in the 1950s to make vaccines against polio. After viruses become inactive with chemicals, they cannot make people sick, but they can provoke the immune system to produce antibodies that can provide long-term protection against living viruses.
Synovac developed Coronavac in early 2020 and then carried out a series of clinical trials. He published his results in November. There they reported that the vaccine appeared safe and provoked an immune response against coronaviruses.
The company then moved to three countries with high Kovid-19 rates in three phases – Brazil, Indonesia and Turkey.
Health officials in Brazil said on Wednesday that the Chinese vaccine had passed safety and efficacy tests that would pave the way for its use in Brazil, but they cited a contractual agreement with Synovac for clinical trials in Brazil Detailed data released from. . Butasan Institute director Dimas Kovas, who conducted the trial, said a joint announcement could be made within two weeks.
“Today is a historic day for science and the health of Brazil,” Sao Paulo state health secretary, Jean Gorinchetin, told a news conference. “This will allow us to save the lives of millions of people not only in Brazil but all over the world.”